Who is sponsoring NCT04374968?

NCT04374968 is sponsored by Henry Ford Health System.

What drugs are being tested in NCT04374968?

Interventions in NCT04374968: Blood flood restriction cuff.

What condition does NCT04374968 study?

NCT04374968 studies Anterior Cruciate Ligament Tear, Knee Injuries, Sport Injury.

Is NCT04374968 still recruiting?

NCT04374968 is currently completed. Last updated 19 July 2023.

Last reviewed 2023-07-19 · How we verify

NCT04374968

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Use of Blood Flow Restriction Therapy Following ACL Tear

Completed NA Last updated 19 July 2023

What this trial tests

NA trial testing Blood flood restriction cuff in Anterior Cruciate Ligament Tear in 50 participants. Completed in 1 May 2022.

Timeline

28 July 2020

Primary endpoint
1 May 2022

1 May 2022

Quick facts

Lead sponsor	Henry Ford Health System
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	50
Start date	28 July 2020
Primary completion	1 May 2022
Estimated completion	1 May 2022
Sites	1 location across United States

Drugs / interventions tested

Blood flood restriction cuff

Conditions studied

Anterior Cruciate Ligament Tear — all drugs for Anterior Cruciate Ligament Tear →
Knee Injuries — all drugs for Knee Injuries →
Sport Injury — all drugs for Sport Injury →

Sponsor

Henry Ford Health System — full company profile →

Who can join

Adults 18 to 60, any sex, with Anterior Cruciate Ligament Tear or Knee Injuries. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Evaluating the use of peri-operative blood flow restriction therapy surrounding anterior cruciate ligament tear

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Effects of a Perioperative Blood Flow Restriction Therapy Program on Early Quadriceps Strength and Patient-Reported Outcomes After Anterior Cruciate Ligament Reconstruction.
Okoroha KR, Tramer JS, Khalil LS, Jildeh TR, et al · · 2023 · cited 11× · PMID 38035216 · DOI 10.1177/23259671231209694

Verify or expand the search:

Other recruiting trials for Anterior Cruciate Ligament Tear

Currently open trials in the same condition.

NCT05174611 — Vitamin D to Improve Quadricep Muscle Strength · Phase 2 · recruiting
NCT06664047 — Over-the-Top vs. Anteromedial ACLR With Lateral Extraarticular Tenodesis · NA · recruiting
NCT06511232 — Intraosseous Morphine Administration During Anterior Cruciate Ligament Reconstruction · Phase 4 · recruiting
NCT06524349 — Utilization of a 3D Printed Customized Knee Extender and At-Home Rehabilitation Program on Patient Outcomes Following AC · NA · active not recruiting
NCT06353503 — Bone Marrow Aspirate Concentrate for Anterior Cruciate Ligament Tear Treatment. · NA · recruiting

Other Henry Ford Health System trials

Trials by the same sponsor.

NCT07450183 — Perioperative Cemiplimab for Resectable Non-Small Cell Lung Cancer With High PD-L1 · Phase 2 · not yet recruiting
NCT07418853 — Comparison of Goniotomy Device Outcomes in Combined Phacoemulsification-goniotomy Surgeries · NA · not yet recruiting
NCT06670287 — The Use of Multiple Sensors to Track Sleep in Nightshift Workers · NA · recruiting
NCT07363525 — Michigan Initial Experience Using Tigertriever for Thrombectomy · not yet recruiting
NCT07530172 — Radioembolization Versus External Radiation Therapy · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04374968 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Henry Ford Health System
Last refreshed: 19 July 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04374968.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing